Published in Int J Cancer on July 15, 2008
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27
Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol (2013) 1.00
Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer. PLoS One (2012) 0.96
HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia (2013) 0.92
Ovarian cancer: opportunity for targeted therapy. J Oncol (2011) 0.90
Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98. Biomed Res Int (2013) 0.89
Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol Syst Biol (2012) 0.88
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch (2012) 0.86
Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Curr Opin Cell Biol (2016) 0.83
MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours. Stem Cells Int (2015) 0.82
The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett (2016) 0.81
HMGA2 is associated with epithelial-mesenchymal transition and can predict poor prognosis in nasopharyngeal carcinoma. Onco Targets Ther (2015) 0.80
Urinary interleukin-1β levels among gynecological patients. J Ovarian Res (2014) 0.79
Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol (2012) 0.79
The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. Nucleic Acids Res (2016) 0.79
Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells. PeerJ (2016) 0.79
Binding the mammalian high mobility group protein AT-hook 2 to AT-rich deoxyoligonucleotides: enthalpy-entropy compensation. Biophys J (2009) 0.79
Effect of silencing of high mobility group A2 gene on gastric cancer MKN-45 cells. World J Gastroenterol (2013) 0.78
FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas. Exp Ther Med (2012) 0.78
Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol (2014) 0.78
Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis. Am J Cancer Res (2016) 0.77
Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML. J Cancer Res Clin Oncol (2015) 0.76
Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468). Adv Pharm Bull (2016) 0.75
MiR-4500 is epigenetically downregulated in colorectal cancer and functions as a novel tumor suppressor by regulating HMGA2. Cancer Biol Ther (2016) 0.75
HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle (2016) 0.75
HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation. Am J Cancer Res (2017) 0.75
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res (2008) 2.36
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79
RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther (2006) 1.65
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol (2011) 1.65
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol (2006) 1.59
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer (2006) 1.53
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm (2010) 1.49
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat (2011) 1.43
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn (2009) 1.38
A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release (2006) 1.37
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer (2007) 1.36
Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol (2010) 1.35
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem (2002) 1.25
Poly(vinyl alcohol) nanofibers by electrospinning as a protein delivery system and the retardation of enzyme release by additional polymer coatings. Biomacromolecules (2005) 1.22
In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol (2009) 1.21
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (2008) 1.19
Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol (2003) 1.15
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood (2002) 1.15
Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol (2008) 1.15
The PDZ-LIM protein RIL modulates actin stress fiber turnover and enhances the association of alpha-actinin with F-actin. Exp Cell Res (2004) 1.15
Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat (2008) 1.14
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch (2005) 1.13
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol (2008) 1.13
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet (2010) 1.12
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res (2009) 1.12
Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol (2010) 1.11
Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem (2003) 1.11
A helminth immunomodulator exploits host signaling events to regulate cytokine production in macrophages. PLoS Pathog (2011) 1.10
Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol (2005) 1.10
Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials (2010) 1.09
Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol (2005) 1.08
Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol (2012) 1.08
Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol (2013) 1.07
An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity. PLoS Genet (2012) 1.07
Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer (2005) 1.07
Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch (2006) 1.05
Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells. J Cell Sci (2007) 1.05
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer (2009) 1.04
PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target (2008) 1.04
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med (2012) 1.04
The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol (2005) 1.03
Extracting information from cDNA arrays. Chaos (2001) 1.02
Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer (2009) 1.02
HuSiDa--the human siRNA database: an open-access database for published functional siRNA sequences and technical details of efficient transfer into recipient cells. Nucleic Acids Res (2005) 1.02
Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med (2010) 1.01
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene (2005) 1.01
Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. Cancer Lett (2006) 1.00
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol (2011) 0.99
Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer (2013) 0.99
CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis (2011) 0.98
Biomarkers downstream of RAS: a search for robust transcriptional targets. Curr Cancer Drug Targets (2010) 0.97
Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci (2006) 0.97
Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia (2009) 0.97
Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology (2009) 0.97
Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch (2012) 0.96
Ultrasensitization: switch-like regulation of cellular signaling by transcriptional induction. PLoS Comput Biol (2005) 0.95
The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. Oncogene (2002) 0.95
Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol (2010) 0.95
Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene (2004) 0.95
Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. Am J Surg Pathol (2015) 0.95
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia (2013) 0.94
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol (2003) 0.94
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol (2010) 0.94
Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns. Mol Genet Genomics (2011) 0.93
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer (2009) 0.93
Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays. J Histochem Cytochem (2011) 0.93
H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling. Am J Pathol (2006) 0.93
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med (2013) 0.92
Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. Cancer Res (2009) 0.92
Nitric oxide mediates apoptosis induction selectively in transformed fibroblasts compared to nontransformed fibroblasts. Carcinogenesis (2002) 0.92
Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Arch (2009) 0.92
De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology (2010) 0.92
Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.91
Physicochemical and biological characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymes. Bioconjug Chem (2004) 0.91
Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology (2010) 0.91
KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J Pathol (2014) 0.90
Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol Biol (2010) 0.90
Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol (2009) 0.90